ATS 2021 will feature presentations of original research from accepted abstracts. Mini Symposia and Thematic Poster Sessions are abstract based sessions.
Please use the form below to browse scientific abstracts and case reports accepted for ATS 2021. Abstracts presented at the ATS 2021 will be published in the Online Abstract Issue of the American Journal of Respiratory and Critical Care Medicine, Volume 203, May 3, 2021.
Search Tips:
- Use the keyword search to search by keyword or author's name.
- Filter your search results by selecting the checkboxes that apply.
- Click on "Clear" to clear the form and start a new search. .
Search results will display below the form.
Real-world Evidence of Reported Symptoms and Quality of Life Burden Associated with Chronic Rhinosinusitis with Nasal Polyposis Across Disease Severity and Region
Session Title
TP6 - TP006 CLINICAL STUDIES OF ALLERGIC AIRWAY DISEASES, LUPUS, AND EOSINOPHILIC DISEASES
Abstract
A1353 - Real-world Evidence of Reported Symptoms and Quality of Life Burden Associated with Chronic Rhinosinusitis with Nasal Polyposis Across Disease Severity and Region
Author Block: S. Chen1, M. Biswas1, M. Scott2, M. Small2, L. Lee2, B. Emmanuel1, S. Ruiz3; 1AstraZeneca, Gaithersburg, MD, United States, 2Adelphi Real World, Bollington, United Kingdom, 3AstraZeneca, Barcelona, Spain.
Rationale: Real-world assessments of symptoms and quality of life (QoL) burden associated with chronic rhinosinusitis with nasal polyposis (CRSwNP) are needed across disease severity and region from both patient and physician perspectives to provide a holistic view. Methods: Data from the Adelphi Real World CRSwNP Disease Specific Programme™ (DSP), a cross-sectional survey among adult patients with bilateral moderate to severe CRSwNP and treating physicians in the US, Europe, and Japan, was utilized. Physicians completed questionnaires on clinical outcomes and disease symptoms, and corresponding patients completed a questionnaire containing individual symptom questions and validated survey instruments to assess symptom burden and impact on quality of life (Sino-Nasal Outcome Test-22 [SNOT-22], EuroQol 5-dimension [EQ-5D], and Work Productivity and Activity Impairment [WPAI]). Assessments were analyzed in the overall survey population and by physician-perceived CRSwNP severity (moderate, severe) and by region (US, Europe, Japan). Results: The overall survey population included 1,296 patients from the US (n=251; 19.4%), Europe (n=820, 63.3%), and Japan (n=225, 19.3%) with moderate (n=1,122, 86.6%) and severe (n=174, 13.4%) CRSwNP. Mean age was 46.9 (SD 15.9) years, with the majority being male (59.6%), non-smokers (86%). The most prevalent comorbidities were allergic rhinitis (49%) and asthma (40%). Severe CRSwNP symptoms were reported by physicians for 13.4% of the overall survey population compared with 25.7% reported by patients. Patients consistently reported higher prevalence and severity for CRSwNP symptoms, including mental and social domains, compared with physician reports in the overall survey population or subpopulation by severity or region. Daily symptoms and severe symptom burden were reported more frequently in severe CRSwNP patients compared with those in moderate patients (Table). Lower quality of life scores (mean SNOT-22 score: severe patients 58.9 [SD 23.3] vs. moderate patients 38.7 [SD 21.0]; mean EQ-5D VAS score: 60.7 [SD 18.9] vs. 71.6 [SD 17.2]; mean EQ-5D index: 0.83 [SD 0.2] vs. 0.92 [SD 0.12]) were also reported in severe patients. Despite variations across regions, the same trends were observed (Table). Levels of absenteeism remained consistent across patients stratified by severity and region; presenteeism impairment score was 41.0% in severe patients compared with 29.6% in the overall survey population. Conclusions: Severe CRSwNP is associated with frequent and severe symptoms and high QoL impact. Physicians underreported CRSwNP symptoms compared with patients across disease severity or region. A more patient-centric view needs to be taken when assessing CRSwNP symptom and QoL burden.
Author Block: S. Chen1, M. Biswas1, M. Scott2, M. Small2, L. Lee2, B. Emmanuel1, S. Ruiz3; 1AstraZeneca, Gaithersburg, MD, United States, 2Adelphi Real World, Bollington, United Kingdom, 3AstraZeneca, Barcelona, Spain.
Rationale: Real-world assessments of symptoms and quality of life (QoL) burden associated with chronic rhinosinusitis with nasal polyposis (CRSwNP) are needed across disease severity and region from both patient and physician perspectives to provide a holistic view. Methods: Data from the Adelphi Real World CRSwNP Disease Specific Programme™ (DSP), a cross-sectional survey among adult patients with bilateral moderate to severe CRSwNP and treating physicians in the US, Europe, and Japan, was utilized. Physicians completed questionnaires on clinical outcomes and disease symptoms, and corresponding patients completed a questionnaire containing individual symptom questions and validated survey instruments to assess symptom burden and impact on quality of life (Sino-Nasal Outcome Test-22 [SNOT-22], EuroQol 5-dimension [EQ-5D], and Work Productivity and Activity Impairment [WPAI]). Assessments were analyzed in the overall survey population and by physician-perceived CRSwNP severity (moderate, severe) and by region (US, Europe, Japan). Results: The overall survey population included 1,296 patients from the US (n=251; 19.4%), Europe (n=820, 63.3%), and Japan (n=225, 19.3%) with moderate (n=1,122, 86.6%) and severe (n=174, 13.4%) CRSwNP. Mean age was 46.9 (SD 15.9) years, with the majority being male (59.6%), non-smokers (86%). The most prevalent comorbidities were allergic rhinitis (49%) and asthma (40%). Severe CRSwNP symptoms were reported by physicians for 13.4% of the overall survey population compared with 25.7% reported by patients. Patients consistently reported higher prevalence and severity for CRSwNP symptoms, including mental and social domains, compared with physician reports in the overall survey population or subpopulation by severity or region. Daily symptoms and severe symptom burden were reported more frequently in severe CRSwNP patients compared with those in moderate patients (Table). Lower quality of life scores (mean SNOT-22 score: severe patients 58.9 [SD 23.3] vs. moderate patients 38.7 [SD 21.0]; mean EQ-5D VAS score: 60.7 [SD 18.9] vs. 71.6 [SD 17.2]; mean EQ-5D index: 0.83 [SD 0.2] vs. 0.92 [SD 0.12]) were also reported in severe patients. Despite variations across regions, the same trends were observed (Table). Levels of absenteeism remained consistent across patients stratified by severity and region; presenteeism impairment score was 41.0% in severe patients compared with 29.6% in the overall survey population. Conclusions: Severe CRSwNP is associated with frequent and severe symptoms and high QoL impact. Physicians underreported CRSwNP symptoms compared with patients across disease severity or region. A more patient-centric view needs to be taken when assessing CRSwNP symptom and QoL burden.
